NASDAQ:PCSA Processa Pharmaceuticals (PCSA) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free PCSA Stock Alerts $1.53 -0.05 (-3.16%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$1.50▼$1.6050-Day Range$1.52▼$2.9952-Week Range$1.40▼$18.00Volume33,043 shsAverage Volume434,364 shsMarket Capitalization$4.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Processa Pharmaceuticals alerts: Email Address Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Processa Pharmaceuticals Stock (NASDAQ:PCSA)Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. Its pipeline includes three Chemotherapy drugs, including Capecitabine, PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; Gemcitabine, PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers; and Irinotecan, PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.Read More PCSA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PCSA Stock News HeadlinesApril 11, 2024 | msn.comU.S. shares lower at close of trade; Dow Jones Industrial Average down 1.09%April 11, 2024 | finance.yahoo.comProcessa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b TrialApril 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 7, 2024 | finance.yahoo.comInsider Buyers At Processa Pharmaceuticals Recover Some Losses, But Still Down US$40kMarch 28, 2024 | nz.finance.yahoo.comEva Mendes says she had 'non-verbal agreement' with Ryan Gosling to be a stay-at-home momMarch 28, 2024 | globenewswire.comProcessa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor ConferenceMarch 25, 2024 | globenewswire.comProcessa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual MeetingFebruary 24, 2024 | msn.comProcessa Pharmaceuticals (PCSA) Price Target Increased by 1900.00% to 81.60April 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.February 21, 2024 | finance.yahoo.comProcessa Pharmaceuticals to Present at the 2024 BIO CEO & Investor ConferenceFebruary 21, 2024 | globenewswire.comProcessa Pharmaceuticals to Present at the 2024 BIO CEO & Investor ConferenceFebruary 14, 2024 | finance.yahoo.comProcessa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual ConferenceFebruary 14, 2024 | globenewswire.comProcessa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual ConferenceFebruary 6, 2024 | markets.businessinsider.comProcessa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleFebruary 6, 2024 | investing.comProcessa Pharmaceuticals Inc (PCSA)February 1, 2024 | finance.yahoo.comProcessa Pharmaceuticals Announces Closing of $7.0 Million Public OfferingFebruary 1, 2024 | msn.comProcessa Pharmaceuticals Announces Offering Pricing DetailsJanuary 27, 2024 | marketwatch.comProcessa Pharmaceuticals Shares Drop 24% After Pricing OfferingJanuary 26, 2024 | msn.comProcessa Pharmaceuticals prices discounted stock and warrants offering to raise $7MJanuary 26, 2024 | msn.comWhat's Going On With Anti Cancer Focused Processa Pharmaceuticals Stock Today?January 26, 2024 | finance.yahoo.comProcessa Pharmaceuticals Announces Pricing of $7.0 Million Public OfferingJanuary 25, 2024 | marketwatch.comProcessa Pharmaceuticals Shares More Than Double After Completing Safety Evaluation of Cancer TreatmentJanuary 25, 2024 | finance.yahoo.comProcessa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 DosesJanuary 20, 2024 | msn.comProcessa Pharmaceuticals Expands NGC-Cap Cancer ProgramJanuary 19, 2024 | finanznachrichten.deProcessa Pharmaceuticals, Inc.: Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast CancerJanuary 19, 2024 | msn.comWhy Processa Pharmaceuticals (PCSA) Stock Is SkyrocketingJanuary 19, 2024 | finance.yahoo.comProcessa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast CancerSee More Headlines Receive PCSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Processa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today4/22/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PCSA CUSIPN/A CIK1533743 Webwww.processapharmaceuticals.com Phone(443) 776-3133Fax443-288-4420Employees15Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($7.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-141.42% Return on Assets-122.25% Debt Debt-to-Equity RatioN/A Current Ratio7.70 Quick Ratio7.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.05 per share Price / Book0.38Miscellaneous Outstanding Shares2,860,000Free Float2,222,000Market Cap$4.38 million OptionableNot Optionable Beta0.53 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. George K. Ng Esq. (Age 50)J.D., Chief Executive Officer Comp: $400.27kDr. David Young Ph.D. (Age 71)Pharm.D., Co-Founder, President of Research and Development & Director Comp: $160.2kDr. Sian E. Bigora Ph.D. (Age 64)Pharm.D., Co-Founder and Chief Development & Regulatory Officer Comp: $184.87kMr. James H. Stanker (Age 66)Chief Financial Officer Comp: $160.2kMr. Patrick Lin (Age 59)Co-Founder, Chief Business & Strategy Officer Comp: $117.15kMs. Wendy J. Guy (Age 60)Co-Founder, Chief Administrative Officer & Corporate Secretary Comp: $94.19kMore ExecutivesKey CompetitorsGenprexNASDAQ:GNPXZyVersa TherapeuticsNASDAQ:ZVSATharimmuneNASDAQ:THARLipella PharmaceuticalsNASDAQ:LIPOKintara TherapeuticsNASDAQ:KTRAView All CompetitorsInsiders & InstitutionsDavid YoungBought 21,000 shares on 2/7/2024Total: $51,450.00 ($2.45/share)Spinnaker TrustBought 76,865 shares on 2/2/2024Ownership: 6.249%Patrick LinBought 2,500 shares on 1/31/2024Total: $5,925.00 ($2.37/share)Justin W YorkeBought 8,000 shares on 1/30/2024Total: $21,520.00 ($2.69/share)George K NgBought 10,000 shares on 1/30/2024Total: $27,000.00 ($2.70/share)View All Insider TransactionsView All Institutional Transactions PCSA Stock Analysis - Frequently Asked Questions Should I buy or sell Processa Pharmaceuticals stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Processa Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PCSA shares. View PCSA analyst ratings or view top-rated stocks. How have PCSA shares performed in 2024? Processa Pharmaceuticals' stock was trading at $6.6920 at the start of the year. Since then, PCSA shares have decreased by 77.1% and is now trading at $1.53. View the best growth stocks for 2024 here. When is Processa Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our PCSA earnings forecast. How were Processa Pharmaceuticals' earnings last quarter? Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) announced its quarterly earnings data on Friday, November, 12th. The company reported ($3.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.60) by $0.20. During the same quarter in the previous year, the business earned ($11.00) EPS. When did Processa Pharmaceuticals' stock split? Processa Pharmaceuticals's stock reverse split before market open on Monday, January 22nd 2024. The 1-20 reverse split was announced on Monday, January 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Processa Pharmaceuticals? Shares of PCSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PCSA) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Processa Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
